Effect of Deproherb soft capsule in migraine patients

The effect of Deproherb soft capsule on quality of life, depression, anxiety and stress of migraine patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220501054717N1

Enrollment

100

Registered

2023-05-15

Start date

2023-05-20

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Migraine. Condition 2: Migraine. Migraine with aura Migraine without aura

Interventions

Intervention 1: Intervention group: Recipient of Deproherb soft capsule (geranium extract) 50 mg manufactured by Barij Essence Company, two capsules daily with meals for two months. Intervention 2: Co

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Their age should be between 18 and 60 years According to the criteria of the International Headache Society ICHD-3, the diagnosis of migraine by a neurologist should be presented to them at least one year before. Diagnosis of moderate to severe migraine

Exclusion criteria

Exclusion criteria: Fever or evidence of infection Having other headaches at the same time History of severe depression Daily use of painkillers Pregnancy or intention to become pregnant Suffering from chronic diseases

Design outcomes

Primary

Measure	Time frame
Stress score in Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire.;The impact of migraine headaches on daily activities. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Migraine-Specific Quality-of-Life Questionnaire (MSQ) questionnaire.;Depression score in Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire.;Anxiety score in Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire.	—

Measure

Time frame

Stress score in Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire.;The impact of migraine headaches on daily activities. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Migraine-Specific Quality-of-Life Questionnaire (MSQ) questionnaire.;Depression score in Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire.;Anxiety score in Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire. Timepoint: At the beginning of the study and after eight weeks of drug use. Method of measurement: Depression, Anxiety and Stress Scale - 21 (DASS-21) questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ali Hosseinian

Shahre-kord University of Medical Sciences

ho3einianali@gmail.com+98 38 3334 2414

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026